StockGuide AI - assistant for market research

Eli Lilly Secures First International Approval for Weight-Loss Drug Foundayo, Competing with Novo Nordisk’s Wegovy in the U.K.

08/11/2026, 02:37 AM business announcement healthcare

Eli Lilly's weight-loss drug Foundayo has received its first approval for sale in the U.K., positioning it to compete directly with Novo Nordisk's Wegovy pill. This approval is significant as it introduces a second GLP-1 weight-loss option in Europe, potentially expanding the market for oral weight-loss medications.

Trivector Research Recommends Investing in 'Non-Tech Compounders' for Strong Returns Beyond AI

08/10/2026, 12:39 PM investing research healthcare consumer

Investors are encouraged to consider 'non-tech compounders' as a strategy to diversify portfolios amid market volatility driven by AI and semiconductor stocks. Trivector Research identifies these companies as having strong growth potential without the risks associated with crowded trades in the tech sector.

The GUARDIAN Study: Pioneering Genetic Testing to Detect Rare Diseases Before Symptoms Appear

08/10/2026, 11:39 AM business research healthcare

Recent advancements in genetic testing are enabling earlier diagnoses of rare diseases, which could significantly improve treatment outcomes and patient care. This shift in screening practices is particularly important for conditions like Batten disease, where early intervention may mitigate severe neurological damage.

Mizuho Adds Walmart (WMT) and Life Time Group Holdings (LTH) to August Top Picks List

08/09/2026, 05:31 AM investing review retail healthcare

Mizuho has identified Walmart and Life Time Group Holdings as top stock picks for August, reflecting a positive market outlook driven by strong earnings and optimism regarding geopolitical developments.

Doximity (DOCS) Shares Surge Over 130% Amid Positive AI Search Tool Comments from CEO Jeffrey Tangney

08/07/2026, 06:36 AM investing stock_growth ai healthcare

Doximity's shares surged over 130% in premarket trading following CEO Jeffrey Tangney's announcement that the company's new AI search tool generates ten times its operational costs, indicating strong profitability potential. This significant rise reflects investor optimism about the company's future growth and profitability in the AI sector.

Eli Lilly Outperforms Novo Nordisk as Market Confidence Diverges Following Earnings Reports

08/06/2026, 07:41 AM business review healthcare

Eli Lilly and Novo Nordisk reported strong second-quarter earnings, but investor reactions diverged significantly, highlighting a growing confidence gap between the two companies in the competitive obesity drug market.

Analysts expect upside for West Pharmaceutical Services (WST) with price target raised to $397 amid GLP-1 drug boom

08/05/2026, 10:36 AM investing forecast Analysts: analysts healthcare

West Pharmaceutical Services is positioned to benefit significantly from the growing demand for injectable drugs, particularly GLP-1 therapies, as it supplies essential packaging solutions that are critical for these medications. With a strong balance sheet and an experienced leadership team, the company is expected to continue its double-digit earnings growth amidst a booming market for biologics and injectables.

CVS Health (CVS) Exceeds Q2 Earnings Estimates and Raises 2026 Guidance Amid Insurance Unit Recovery

08/05/2026, 04:38 AM business forecast healthcare

CVS Health reported stronger-than-expected second-quarter earnings and revenue, prompting an increase in its 2026 guidance, driven by improvements in its insurance unit Aetna. This positive performance is significant for investors as it reflects a recovery in the healthcare sector amid ongoing challenges.

Eli Lilly (LLY) Reports Strong Q2 Earnings, Raises Full-Year Revenue Outlook Amid Surge in Zepbound and Mounjaro Sales

08/05/2026, 04:38 AM business forecast healthcare

Eli Lilly's strong second-quarter earnings and revenue, driven by robust sales of its weight loss and diabetes drugs, have led the company to raise its full-year revenue outlook significantly, indicating strong market demand and growth potential.

Analysts Citi express concerns over Novo Nordisk’s (NVO) growth prospects despite raised guidance

08/04/2026, 11:35 PM business research Analysts: analysts, Citi healthcare

Novo Nordisk's recent quarterly results and raised guidance have not alleviated investor concerns regarding its long-term growth prospects amid increasing competition from Eli Lilly's obesity drugs. The company's ability to maintain momentum in the U.S. market remains uncertain.

Topic: healthcare